A new test to analyze gene expression in lymphoma patients
Official title: A multiplex platform for quantitative analysis of clinically important gene expression signatures
Funded at Kasa Bio, L.l.c. · NIH-10920595 · Data updated 2026-11-12
This study is testing a new test that helps doctors understand the different types of diffuse large B-cell lymphoma (DLBCL) so they can choose the best treatment for patients, making the process quicker and more affordable.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kasa Bio, L.l.c. NIH-funded |
| Lab location | 1 site (Peachtree Corners, UNITED STATES) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $297,458 |
| NIH project number | 1R43GM155903-01A1 |
| Project ID | NIH-10920595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma, particularly those needing subtype differentiation for treatment planning.
✕Less likely to help
Patients with other types of lymphoma or those not diagnosed with diffuse large B-cell lymphoma may not benefit from this research.
What this research studies
This research focuses on developing a novel assay to analyze gene expression signatures in patients with diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of lymphoma. The proposed Zip-MeltTM DLBCL Classifier Assay will allow for the differentiation of two major subtypes of DLBCL, which is crucial for determining the most effective treatment. By utilizing a single reaction to analyze multiple genes, this approach aims to reduce healthcare costs and improve turnaround times for results, making it more accessible for clinical use. Patients will benefit from a more efficient diagnostic process that can lead to better-targeted therapies.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and cost-effective diagnostics for lymphoma patients, improving treatment outcomes.
How similar studies have gone: Similar multiplexing approaches in gene expression analysis have shown promise in other cancers, indicating potential success for this novel assay.
Where this research is happening
-
Kasa Bio, L.l.c.
Peachtree Corners, United States Active
Researchers
- Principal investigator: Madanahally Divakar, Kiran — Kasa Bio, L.l.c.
- Study coordinator: Madanahally Divakar, Kiran
Related research
Other NIH-funded projects on the same topics.
-
A new technology to improve DNA and RNA testing methods
This study is working on a new testing method that can quickly check for several DNA or RNA markers at once, making it easier and cheaper for labs to provide accurate diagnoses for conditions like acute lymphoblastic leukemia, which could help patients get the care they need faster.
-
A new method for screening liver diseases using multiple miRNA markers
This study is working on a new, affordable way to quickly check for several tiny molecules in your body that can help spot liver diseases linked to alcohol use and diabetes, making it easier for doctors to catch these issues early and keep track of your health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.